olodaterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 4814 868049-49-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olodaterol
  • olodaterol hydrochloride
  • BI 1744 CL
  • striverdi respimat
  • olodaterol HCl
  • BI 1744
  • BI-1744
a long-acting beta2-adrenergic agonist (LABA), activation of beta2 receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3',5' adenosine monophosphate (cAMP), elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells
  • Molecular weight: 386.45
  • Formula: C21H26N2O5
  • CLOGP: 1.44
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 4
  • TPSA: 100.05
  • ALOGS: -3.74
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mcg Inhal.solution

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 15.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.45 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 31, 2014 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wheezing 45.70 35.53 21 615 116643 79627109

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AC19 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03AL06 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA MoA N0000009922 Adrenergic beta2-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
FDA EPC N0000175779 beta2-Adrenergic Agonist
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35523 bronchodilator

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic obstructive lung disease indication 13645005 DOID:3083




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.32 acidic
pKa2 11.96 acidic
pKa3 13.95 acidic
pKa4 8.47 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 8044046 Nov. 10, 2023 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 8044046 Nov. 10, 2023 TREATMENT OF COPD
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 7220742 May 12, 2025 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 8034809 May 12, 2025 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 7220742 May 12, 2025 TREATMENT OF RESPIRATORY COMPLAINTS
EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 8034809 May 12, 2025 TREATMENT OF COPD
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 7396341 Oct. 10, 2026 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 9.14 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-1 adrenergic receptor GPCR Ki 7.33 SCIENTIFIC LITERATURE
Beta-3 adrenergic receptor GPCR Ki 5.26 SCIENTIFIC LITERATURE

External reference:

IDSource
D10020 KEGG_DRUG
4033628 VUID
N0000190930 NUI
869477-96-3 SECONDARY_CAS_RN
4033628 VANDF
4033629 VANDF
CHEBI:82700 CHEBI
DZQ PDB_CHEM_ID
CHEMBL605846 ChEMBL_ID
C549647 MESH_SUPPLEMENTAL_RECORD_UI
7543 IUPHAR_LIGAND_ID
9174 INN_ID
DB09080 DRUGBANK_ID
VD2YSN1AFD UNII
1546059 RXNORM
220486 MMSL
30305 MMSL
d08261 MMSL
015412 NDDF
015413 NDDF
704459002 SNOMEDCT_US
704460007 SNOMEDCT_US
715600003 SNOMEDCT_US
C2934193 UMLSCUI
CHEMBL2105743 ChEMBL_ID
11504295 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Stiolto Respimat HUMAN PRESCRIPTION DRUG LABEL 2 0597-0155 SPRAY, METERED 2.74 ug RESPIRATORY (INHALATION) NDA 31 sections
Stiolto Respimat HUMAN PRESCRIPTION DRUG LABEL 2 0597-0155 SPRAY, METERED 2.74 ug RESPIRATORY (INHALATION) NDA 31 sections
Striverdi Respimat HUMAN PRESCRIPTION DRUG LABEL 1 0597-0192 SPRAY, METERED 2.50 ug RESPIRATORY (INHALATION) NDA 31 sections
Striverdi Respimat HUMAN PRESCRIPTION DRUG LABEL 1 0597-0192 SPRAY, METERED 2.50 ug RESPIRATORY (INHALATION) NDA 31 sections